A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
Completed
The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardiovascular risk.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
08/22/2025
Locations: MultiCare Good Samaritan Hospital, Puyallup, Washington +3 locations
Conditions: Type 2 Diabetes Mellitus
A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
Active Not Recruiting
We are doing this study to learn more about how tirzepatide may help fight chronic kidney disease in people with obesity with or without type 2 diabetes (T2D). The study will last about 56 weeks and include up to 12 visits.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/21/2025
Locations: University of Washington Medical Center - Montlake, Seattle, Washington +1 locations
Conditions: Overweight, Obesity, Chronic Kidney Disease, Type 2 Diabetes, T2D
A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)
Recruiting
The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe PsA and obesity or overweight with at least 1 weight-related comorbidity. The study will last up to 12 months.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: Seattle Rheumatology Associates PLLC, Seattle, Washington +1 locations
Conditions: Psoriatic Arthritis, Overweight or Obesity
Tirzepatide in PWS, HO and GNSO
Recruiting
This research study is comparing the effectiveness of a weight loss medication called Tirzepatide in young adults with Prader-Willi Syndrome and/or hypothalamic obesity, as compared to young adults with obesity that is unrelated to a genetic syndrome or underlying medical cause. These groups will be given medication for 1 year to see how weight and other health factors are effected by the medication.
Gender:
ALL
Ages:
Between 18 years and 26 years
Trial Updated:
05/14/2025
Locations: Seattle Children's Hospital, Seattle, Washington
Conditions: Prader-Willi Syndrome, Hypothalamic Obesity, Obesity/Therapy
A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)
Completed
The purpose of this study is to see if the study drug, tirzepatide administered once weekly, is safe and effective as a treatment for Nonalcoholic Steatohepatitis (NASH).
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
01/22/2025
Locations: Harborview Medical Center/University of Washington, Seattle, Washington
Conditions: Nonalcoholic Steatohepatitis